Immunogenic compositions containing phospholipid

Details Immunogenic compositions containing phospholipid Immunogenic compositions containing phospholipid

2003-12-29

2011-10-11

Minnifield, Nita M (Department: 1645)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C424S184100, C424S234100, C424S278100, C424S489000, C424S486000, C424S450000, C424S451000, C424S490000

Reexamination Certificate

active

08034378

ABSTRACT:
Immunogenic compositions containing phospholipid adjuvants, including microparticle and emulsion compositions. According to one aspect of the invention, an immunogenic microparticle composition is provided that comprises: water; a polymer microparticle comprising a biodegradable polymer, e.g., a polymer selected from a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate; an antigen adsorbed to the microparticle; and a phospholipid compound, e.g., a synthetic phospholipid compound comprising: (i) one or more phosphoryl groups independently selected from a phosphate group and a phosphodiester group; (ii) a plurality of linear alkane groups. According to another aspect of the invention an immunogenic emulsion composition is provided that comprises: water; a metabolizable oil; an emulsifying agent; an antigen; and a phospholipid compound, e.g., a synthetic phospholipid compound like that above. The emulsion composition is an oil-in-water emulsion having oil and aqueous phases, in which the oil phase is in the form of oil droplets, substantially all of which are less than 1 micron in diameter.

REFERENCES:
patent: 5603960 (1997-02-01), O'Hagan et al.
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6290973 (2001-09-01), Hawkins et al.
patent: 6303347 (2001-10-01), Johnson et al.
patent: 6306405 (2001-10-01), O'Hagan et al.
patent: 6355257 (2002-03-01), Johnson et al.
patent: 6372227 (2002-04-01), Garcon et al.
patent: 6451325 (2002-09-01), Van Nest et al.
patent: 6458370 (2002-10-01), O'Hagan et al.
patent: 6465633 (2002-10-01), Skeiky
patent: 6534064 (2003-03-01), O'Hagan et al.
patent: 6824793 (2004-11-01), O'Hagan et al.
patent: 6855492 (2005-02-01), O'Hagan et al.
patent: 6861410 (2005-03-01), Ott et al.
patent: 6884435 (2005-04-01), O'Hagan et al.
patent: 7090853 (2006-08-01), Kapp et al.
patent: 7357936 (2008-04-01), Garcon
patent: 7393630 (2008-07-01), O'Hagan et al.
patent: 7550145 (2009-06-01), O'Hagan et al.
patent: 7604802 (2009-10-01), O'Hagan et al.
patent: 7641911 (2010-01-01), Ott et al.
patent: 7731967 (2010-06-01), O'Hagan et al.
patent: 2002/0002272 (2002-01-01), Houghton et al.
patent: 2002/0025329 (2002-02-01), O'Hagan et al.
patent: 2002/0136776 (2002-09-01), Fang et al.
patent: 2002/0183251 (2002-12-01), Xu et al.
patent: 2003/0138453 (2003-07-01), O'Hagan et al.
patent: 2003/0170273 (2003-09-01), O'Hagan et al.
patent: 2004/0191270 (2004-09-01), Drane et al.
patent: 2004/0202669 (2004-10-01), O'Hagan
patent: 2005/0118275 (2005-06-01), O'Hagan
patent: 2005/0169979 (2005-08-01), Michaeli et al.
patent: 2005/0245464 (2005-11-01), Yedgar
patent: 2007/0077253 (2007-04-01), Haynie
patent: 2009/0139636 (2009-06-01), Bauer et al.
patent: 2010/0003280 (2010-01-01), O'Hagan et al.
patent: 2010/0047271 (2010-02-01), Drane et al.
patent: 2010/0150994 (2010-06-01), Kotyla
patent: 2010/0173854 (2010-07-01), Dominowski et al.
patent: WO 92/00081 (1992-01-01), None
patent: WO 98/33487 (1998-08-01), None
patent: WO 00/06123 (2000-02-01), None
patent: WO 00/50006 (2000-08-01), None
patent: WO 00/56282 (2000-09-01), None
patent: WO 01/36599 (2001-05-01), None
patent: WO 01/81609 (2001-11-01), None
patent: WO 02/03961 (2002-01-01), None
patent: WO 02/26209 (2002-04-01), None
patent: WO 02/26212 (2002-04-01), None
patent: WO 03/028661 (2003-04-01), None
patent: WO 03/070909 (2003-08-01), None
O'Hagan et al, Vaccine, 1989, 7/5:421-424 abstract only.
Zauner et al, Biol. Chem. 2001, 382:581-595.
Kersten et al, Expert Rev. Vaccines, 2004, 3/4:453-462.
Alving, Vaccine, 2002, 20:S56-S64.
Haining et al, J. Immunology, 2004, 173:2578-2585.
Fortin et al, J. Histochemistry and Cytochemistry, 2001, 49/11:1407-1420.
O'Hagan et al, Advanced Drug Delivery Reviews, 1998, 32:225-246.
O'Hagan et al, Molecular Medicine Today, Feb. 1997, pp. 69-75.
Giuliani et al, PNAS, 2006, 103/29:10834-10839.
Gupta et al, Vaccine, 1995, 13/14:1263-1276.
O'Hagan et al, Vaccine, 2000, 18:1793-1801.
Dhiman et al, FEMS Immunology and Medical Microbiology, 1998, 21:19-28.
O'Hagan et al, Biomolecular Engineering, 2001, 18:69-85.
Gregoriadis, Immunology Today, 1990, 11/3:89-97.
O'Hagan, In: New Generation Vaccines, ed. Levine et al, 2004, pp. 259-270.
Muderhwa et al, J. Pharmaceutical Sciences, 1999, 88/12:1332-1339.
Vordermeier et al, Vaccine, 1995, 13/16:1576-1582.
Haining et al, Blood, Nov. 16, 2002, 100/11:Abstract No. 2648 abstract only.
Muttilainen et al, Microbial Pathogenesis, 1995, 18:423-436.
Cox et al, Vaccine, 1997, 15/3:248-256.
Delgado et al, Vaccine, 1999, 17:2927-2938.
Kwissa et al, Expert Rev. Vaccines, 2007, 6/5:673-684.
Singh et al, Expert Rev. Vaccines, 2007, 6/5:797-808.
M. Briones et al., “The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Therapy,”Pharmaceutical Research, vol. 18, No. 5, 2001, pp. 709-712.
J. Kazzaz et al., “Novel Anionic Microparticles Are a Potent Adjuvant for the Induction of Cytotoxic T Lymphocytes Against Recombinant p55 Gag from HIV-1,”Journal of Controlled Release, vol. 67, 2000, pp. 347-356.
K.S. Denis-Mize et al., “Plasmid DNA Adsorbed onto Cationic Microparticles Mediates Target Gene Expression and Antigen Presentation by Dendritic Cells,”GeneTherapy, vol. 7, 2000, pp. 2105-2112.
Manmohan Singh et al., “Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA,”Pharmaceutical Research, vol. 18, No. 10, Oct. 2001, pp. 1476-1479.
Manmohan Singh et al., “Cationic Microparticles: A Potent Delivery System for DNA Vaccines,”Proceedings of the National Academy of Science USA, vol. 97, No. 2, Jan. 18, 2000, pp. 811-816.
Manmohan Singh et al., “Mucosal Immunization with HIV-1 Gag DNA on Cationic Microparticles Prolongs Gene Expression and Enhances Local and Systemic Immunity,”Vaccine, vol. 20, 2002, pp. 594-602.
Derek O'Hagan et al., “Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines,”Journal of Virology, vol. 75, No. 19, Oct. 2001, pp. 9037-9043.
Hawkins, Lynn D. et al., “A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-Like Receptor 4-Dependent Immunostimulatory Action, and Adjuvant Activity,”Journal of Pharmacology and Experimental Therapeutics, vol. 300, No. 2, 2002, pp. 655-661.
Johnson, David A., “Synthesis and Biological Evaluation of a New Class of Vaccine Adjuvants: Aminoalkyl Glucosaminide 4-Phosphates (AGPs),”Bioorganic&Medicinal Chemistry Letters, vol. 9, 1999, pp. 2273-2278.

Affiliated with

Also associated with

Rating

Immunogenic compositions containing phospholipid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic compositions containing phospholipid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic compositions containing phospholipid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4273852